Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
MICHEL GERARD J reported acquisition or exercise transactions in this Form 4 filing.
Beta Bionics, Inc. director MICHEL GERARD J received an equity grant of 16,965 shares of Common Stock on May 21, 2026. The award is structured as a restricted stock unit grant under the company’s 2025 Equity Incentive Plan and was issued at no cash cost, raising his direct holdings to 33,509 shares.
Beta Bionics, Inc. director Christy Jones reported both a stock award and a small share sale. On May 21, 2026, Jones received a grant of 16,965 shares of common stock as a restricted stock unit award under the company’s 2025 Equity Incentive Plan, at no cash cost.
On the same date, Jones sold 1,998 common shares at $9.95 per share in an open‑market transaction. According to the filing, this sale was made pursuant to a Rule 10b5‑1 trading plan adopted on February 19, 2026, and Jones held 13,246 common shares directly after the sale.
Palasis Maria reported acquisition or exercise transactions in this Form 4 filing.
Beta Bionics, Inc. director Maria Palasis received an equity award of 16,965 shares of Common Stock on May 21, 2026. The grant was issued at no cash cost as a restricted stock unit award under the company’s 2025 Equity Incentive Plan, bringing her direct holdings to 29,397 shares.
Dearen Danny L. reported acquisition or exercise transactions in this Form 4 filing.
Beta Bionics, Inc. director Danny L. Dearen reported receiving an equity grant in the form of restricted stock units. On May 21, 2026, he was awarded 16,965 shares of common stock at a stated price of $0.00 per share under the company’s 2025 Equity Incentive Plan. After this award, his direct holdings increased to 32,209 shares of common stock. This is a compensation-related grant rather than an open-market purchase or sale.
CARNEY SEAN reported acquisition or exercise transactions in this Form 4 filing.
Beta Bionics, Inc. director Sean Carney received a grant of 16,965 shares of common stock as a restricted stock unit award under the company’s 2025 Equity Incentive Plan. The award was recorded at a price of $0.00 per share, bringing his direct holdings to 32,209 shares after the grant.
Beta Bionics, Inc. director Adam Lezack reported a mix of stock awards and small planned sales. On May 21, 2026, he received a grant of 16,965 shares of Common Stock at no cost, described as a restricted stock unit award under the company’s 2025 Equity Incentive Plan.
That same day he executed an open-market sale of 1,000 shares at $9.95 per share, followed by a sale of 998 shares at $11.21 per share on May 22, 2026. The filing shows he held 27,399 shares directly after the most recent sale. Both sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance rather than timed discretionarily.
Beta Bionics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of March 23, 2026, there were 44,561,695 shares outstanding, and a quorum of 36,061,048 shares was represented in person or by proxy.
Stockholders elected Class I directors Sean D. Carney and Christy Jones to serve until the 2029 Annual Meeting, with Carney receiving 30,659,060 votes for and Jones 25,865,542 votes for, alongside broker non-votes. Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Beta Bionics, Inc. has updated expectations for Mint, its patch insulin pump in development. The company now expects to fully commercialize Mint by the end of the second quarter of 2027, subject to U.S. FDA regulatory clearance of its alternate controller enabled (ACE) insulin pump 510(k) application.
The new timeline reflects the FDA’s initial responses to that application and progress in scaling Mint manufacturing, and the company expects capacity to meet anticipated demand at launch. Mint is expected to offer a 200‑unit insulin reservoir, about three days of wear plus a 12‑hour grace period, smartphone control, waterproof use, and compatibility with leading continuous glucose monitors and Beta Bionics’ FDA‑approved fully adaptive dosing algorithm.